Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hamada, T. Kumamoto, A. Harumatsu, K. Mizuno, T. Samukawa, I. Higashimoto, M. Watanabe, H. Inoue (Kagoshima, Japan). B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases. Eur Respir J 2013; 42: Suppl. 57, 5116

Member's Comments

No comment yet.

Related content which might interest you: Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Chemical exposure triggering connective tissue disease with lung involvement Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 Connective tissue disease-related interstitial lung disease and lung cancer Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 A clinicopathological review of interstitial pneumonia with marked IgG4 positive plasma cells infiltration Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27 Year: 2005 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Endothelin-1 induced connective tissue growth factor expression in human lung fibroblasts by ETAR-dependent JNK/AP-1 pathway Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up? Source: International Congress 2016 – Connective tissue disorders Year: 2016 HCMV infection triggers the development of interstitial lung diseases in autoimmune disorders Source: International Congress 2014 – IPF and surroundings Year: 2014 Connective tissue disease-associated interstitial lung diseases and interstitial pneumonia with autoimmune features: different entities? Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020